REMS “Abuses” Concern FDA, But Can Scolding Help Speed Generic Entry?
This article was originally published in RPM Report
Executive Summary
Brand name companies’ use of restricted distribution programs to block the development of generic drugs has been an unintended consequence of the FDA Amendments Act of 2007. The generics industry has long complained that the use of FDA-required risk management plans prevents access to affordable medicines. While that battle has ranged in the courts, FDA has remained quiet on the subject. Until now.
You may also be interested in...
REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill
Sen. Leahy's reintroduced CREATES Act allows generic sponsors to sue innovators who fail to provide sufficient quantities of REMS covered products, but seems to give wide latitude to courts; bill reflects Congress' broader focus on generic drugs to address drug pricing issue.
REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill
Sen. Leahy's reintroduced CREATES Act allows generic sponsors to sue innovators who fail to provide sufficient quantities of REMS covered products, but seems to give wide latitude to courts; bill reflects Congress' broader focus on generic drugs to address drug pricing issue.
REMS Abuses: Congressional Panel’s Focus Turns To Federal Trade Commission
During bipartisan, but one-sided, hearing about US FDA’s limited authority to ensure generic drug makers can access restricted distribution reference products for bioequivalence testing, one lawmaker wants to know what FTC is doing about the issue.